Monopar Therapeutics (MNPR) Short term Debt (2020)
Monopar Therapeutics (MNPR) reported Short term Debt of $67772.0 for Q3 2020, up 43.04% sequentially from $47379.0 in Q2 2020.
Monopar Therapeutics (MNPR) Short term Debt (2020) Analysis & Trends
Monopar Therapeutics (MNPR) has 1 years of Short term Debt data on file, last reported at $67772.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Monopar Therapeutics | 707.36 Mn | 645.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 67,772.00 |
| Jun 30, 2020 | 47,379.00 |